e-Drug3D 1514 |
cas 873857-62-6 |
CLASS ANTIINFECTIVES |
ROUTE (list) ORAL |
ATC code |
PK parameters Tmax 2 HOUR |
Target TARGET BETA SUBUNIT OF RNA POLYMERASE PDB Ligand code = FI8 (link to the list of PDB complexes) Download experimental 3D coordinates of FI8 with added hydrogens |
DrugCentral DNA-directed RNA polymerase UNIPROT Q182S6 rpoZ |
Download SDF file | Oxacyclooctadeca-3,5,9,13,15-pentaen-2-one, 3-[[[6-deoxy-4-O-(3,5-dichloro-2-ethyl-4,6-dihydroxybenzoyl)-2-O-methyl-�-D-mannopyranosyl]oxy]methyl]-12-[[6-deoxy-5-C-methyl-4-O-(2-methyl-1-oxopropyl)-�-D-lyxo-hexopyranosyl]oxy]-11-ethyl-8-hydroxy-18-[(1R)-1-hydroxyethyl]-9,13,15-trimethyl-, (3E,5E,8S,9E,11S,12R,13E,15E,18S)- Formula: Calculated chemical properties: MW 1058.01 NB_atoms 72 XLogP 6.23 PSA 249.382 NB_HD 7 NB_HA 18 fsp3 0.63 Lipinski(0=no;1=yes) 0 |
FDA NDA 201699 (label) INN (FIDAXOMICIN) DIFICID (CUBIST PHARMS LLC) APPROVAL= AP YEAR= 2011 NEWMOLECULARENTITY NDA 213138 (label) INN (FIDAXOMICIN) DIFICID (CUBIST PHARMS LLC) APPROVAL= AP YEAR= 2020 NDA 208443 (pdf not found) INN (FIDAXOMICIN) FIDAXOMICIN (ACTAVIS LABS FL) APPROVAL= AP YEAR= 2024 NDA 219559 (pdf not found) INN (FIDAXOMICIN) FIDAXOMICIN (APOTEX) APPROVAL= AP YEAR= 2026 NDA 220374 (pdf not found) INN (FIDAXOMICIN) FIDAXOMICIN (TORRENT) APPROVAL= AP YEAR= 2026 |
Other links: | |
e-Drug3D 1535 |
cas 1030825-28-5 |
CLASS ANTIINFECTIVES |
ROUTE (list) - |
ATC code |
PK parameters Tmax 1.02 HOUR |
Target TARGET BETA SUBUNIT OF RNA POLYMERASE |
DrugCentral DNA-directed RNA polymerase UNIPROT Q182S6 rpoZ |
Download SDF file | Oxacyclooctadeca-3,5,9,13,15-pentaen-2-one, 3-[[[6-deoxy-4-O-(3,5-dichloro-2-ethyl-4,6-dihydroxybenzoyl)-2-O-methyl-β-L-mannopyranosyl]oxy]methyl]-12-[(6-deoxy-5-C-methyl-β-D-lyxo-hexopyranosyl)oxy]-11-ethyl-8-hydroxy-18-[(1R)-1-hydroxyethyl]-9,13,15-trimethyl-, (3E,5E,8S,9E,11S,12R,13E,15E,18S)- Formula: Calculated chemical properties: MW 987.92 NB_atoms 67 XLogP 5.03 PSA 247.113 NB_HD 8 NB_HA 17 fsp3 0.62 Lipinski(0=no;1=yes) 0 |
FDA - |
Other links: |